Clinical

Assessing a patient’s understanding of his or her own illness is important as cancer treatments become more and more complex, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.

Better care for high-need, high-cost patients will require targeted care delivery models based on integrated data networks that include clinical, genomic, and social information. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.

Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

Fragility fractures are a serious complication of type 1 and type 2 diabetes, but many clinicians who treat patients with diabetes are not aware of the increased risk of these fractures.

A substantial number of prescribers did not regard nonselective beta blockers as contraindicated, suggesting the need for improvement programs that target the prescribers’ awareness and knowledge.

A new study aimed to assess the prevalence of allergic sensitization, asthma, eczema, and hay fever from infancy to adulthood, finding that patterns of atopic disorders vary throughout childhood.

Group 2 innate lymphoid cells, a rare form of lymphocyte that defend the body from pathogens, may have immune-regulatory functions in rheumatoid arthritis and play a key role in the development of inflammatory arthritis, according to immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg.

The first patient has been treated in a phase 2b dose-confirmation study of AMT-061, an investigational gene therapy for the treatment of patients with severe and moderately severe hemophilia B. Once the dosing of AMT-061 is confirmed, the safety and efficacy of the therapy will be evaluated in the global phase 3 HOPE-B clinical trial.

Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center, explains why the Joslin Diabetes Center and the American Diabetes Association oppose the decision by the American College of Physicians to recommend a higher A1C target across the board.

A new technology platform utilizing artificial intelligence (AI) could change how drug combinations are designed and help doctors to identify optimal personalized drug combinations for patients with multiple myeloma.

The FDA will start to review gene therapy experiments and products the same as other treatments and drugs; Alaska and Minnesota have become models for other states looking to curb health insurance premium increases with reinsurance programs; patients with limited English proficiency often have to rely on family members and friends to interpret for them, which can have serious consequences.

The 2018 International AIDS Conference in Amsterdam brought a plethora of new clinical implications for HIV care, reflecting ongoing investments in research efforts and optimism across all clinical domains, including vaccines, prevention, and new treatment approaches. However, with the excitement also came caution in other areas, such as stagnant incidence rates.

People living with HIV are twice as likely to develop cardiovascular disease and the global burden of HIV associated with cardiovascular disease has tripled over the last 2 decades.

While the prevalence of migraine was significantly higher among patients with diabetes, the disease, itself, was not associated with a greater risk of migraine.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The Joslin Clinical Guidelines are designed to be streamlined and disseminated as widely as possible, explained Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center.

Treatment options for patients with acute myeloid leukemia (AML) who relapse after an allogeneic hematopoietic cell transplant (allo-HCT) are limited, but those who are able to receive intensive interventions receive a second allo-HCT or donor lymphocyte infusion. A study in JAMA Oncology sought to compare the 2 options for patients who relapse.

Multiple sclerosis (MS) involves the progressive loss of the protective layer of nerve fibers, myelin, and its loss, called demyelination, results in symptoms of MS. Blocking the protein receptor, muscarinic type 3 (M3R), may be effective in promoting remyelination in patients with MS, based on the results of a study published by the Journal of Neuroscience.